Aardvark Therapeutics (AARD)

Executive Summary

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing a novel gut-brain approach to treat metabolic diseases by targeting the neurological drive of hunger. Its lead oral compound, ARD-101, activates bitter taste receptors in the digestive tract to stimulate satiety hormones, offering a potentially safer, peripherally-acting therapy for hyperphagia and obesity. The company has completed multiple Phase 2 trials in obesity, bariatric surgery, and autism, demonstrating proof-of-concept. Currently, ARD-101 is in Phase 3 development for Prader-Willi Syndrome (PWS), a rare genetic disorder characterized by severe hyperphagia. Two Phase 3 trials are active: one with enrollment completed and topline data expected in early 2026, and a larger long-term study ongoing. Positive results could support a regulatory filing and establish ARD-101 as a first-in-class treatment for PWS. Beyond PWS, Aardvark is positioned to expand into broader obesity and metabolic indications, leveraging its unique peripheral mechanism that may avoid central nervous system side effects. The company's pipeline also includes ARD-501 for autism, though earlier stage. With a strong scientific rationale, validated Phase 2 data, and a clear path to registration in PWS, Aardvark represents a compelling opportunity in the metabolic disease space.

Upcoming Catalysts (preview)

• Q2 2026Topline Phase 3 Data for ARD-101 in Prader-Willi Syndrome (NCT06828861)60% success
• Q4 2026Initiation or Update on Second Phase 3 PWS Trial (NCT07197034)80% success
• TBDPotential Partnership or Phase 2b/3 Start for ARD-101 in Obesity40% success